Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.

Current opinion in oncology - 1 Nov 2007

Pikman Yana, Levine Ross L

Abstract excerpt

PURPOSE OF REVIEW: The identification and characterization of somatic disease alleles have greatly improved our understanding of the molecular pathogenesis of myeloproliferative disorders. This review focuses on recent studies investigating the role of activated tyrosine kinase signaling in the Philadelphia chromosome negative myeloproliferative disorders. RECENT FINDINGS: Previously identified tyrosine kinase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Disease
Share to Janus Kinase 2
Share to Myeloproliferative Disorders

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Philadelphia Chromosome

Share to Primary Myelofibrosis

Share to Protein-Tyrosine Kinases

Share to Receptors, Thrombopoietin

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 17906464
DOI: 10.1097/CCO.0b013e3282f0e20c

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.PMID 17906464Read ↗

Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications.Semantic proximity Read ↗

Philadelphia Chromosome–Negative Myeloproliferative Disorders: Biology and TreatmentSemantic proximity Read ↗

JAK2 kinase inhibitors and myeloproliferative disordersSemantic proximity Read ↗

Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.Semantic proximity Read ↗

Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F EraSemantic proximity Read ↗

Jak-2 positive myeloproliferative neoplasms.Semantic proximity Read ↗

Genetic basis of MPN: Beyond JAK2-V617F.Semantic proximity Read ↗

Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.Semantic proximity Read ↗

The spectrum of JAK2-positive myeloproliferative neoplasmsSemantic proximity Read ↗

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.Semantic proximity Read ↗

Molecular markers guide diagnosis and treatment in Philadelphia chromosome-negative myeloproliferative disorders (Review).Semantic proximity Read ↗

Molecular and genetic bases of myeloproliferative disorders: questions and perspectives.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.